Dr. Martin Roland Jensen – Chairman
Dr. Martin Roland Jensen (born 1960) has extensive leadership experience from the biopharmaceutical industry and as a serial entrepreneur has founded and co-founded several biotech companies. He also has extensive experience with scientific work, mainly in immunology, cell biology and development of cancer vaccines. Dr. Jensen has a doctorate in cell and molecular biology from the University of Copenhagen. Dr. Jensen is a co-founder of the Company.
Dr. Allan Rosetzsky – Board Member
Dr. Allan Rosetzsky (born in 1948) graduated as a Doctor of Medicine from the University of Copenhagen in 1973 and following worked in the Danish health system for years. Dr. Rosetzsky also held several leading positions within drug development of the Rhone-Poulenc Group. In addition, he has founded, developed and run his own company, KLIFO, working internationally with contract research. Dr. Rosetzsky is furthermore active in the Business Angels Öresund.
Gitte Pedersen – Board Member
Gitte Pedersen (born 1963) holds a Master’s degree in chemical engineering and a Graduate diploma in business science. Pedersen has over 20 years’ experience from the biotech and pharma industry. She has worked at Novo Nordisk R&D, production and marketing, as well as marketing with global responsibility for a large product portfolio. Gitte Pedersen has acted as a business advisor to the biotech and pharma companies in both early and later stages in North America. In this role, she also acted as advisor to the Danish Foreign Ministry and has secured business for several billion USD for companies in the Danish biotech industry. Gitte Pedersen has founded the companies Genomic Expression and Legomics.
Jakob Knudsen – Board Member
Jakob Knudsen is CEO of Virogates A/S, an international biotechnology company located in Denmark. He has an education as a lawyer from the University of Copenhagen, DK, and an MBA from Imperial College, UK. Following his graduation in 1994, Jakob Knudsen has built up extensive experience in commercial operations, including IP, marketing and finance. He has held various positions at ALK-Abelló A/S, a listed mid-sized biotechnology company, where he headed Corporate Business Development. Furthermore, he has held positions as CCO and CFO at the Pharmaceutical company Egalet Ltd.